EA202190576A1 - Полиморфные соединения и их применение - Google Patents

Полиморфные соединения и их применение

Info

Publication number
EA202190576A1
EA202190576A1 EA202190576A EA202190576A EA202190576A1 EA 202190576 A1 EA202190576 A1 EA 202190576A1 EA 202190576 A EA202190576 A EA 202190576A EA 202190576 A EA202190576 A EA 202190576A EA 202190576 A1 EA202190576 A1 EA 202190576A1
Authority
EA
Eurasian Patent Office
Prior art keywords
application
polymorphic compounds
compounds
polymorphic
stroke
Prior art date
Application number
EA202190576A
Other languages
English (en)
Inventor
Расселл Бёрч Поу
Дэвид Т. Джонаитис
Лиза Мишель Грув
Original Assignee
Астросайт Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астросайт Фармасьютикалс, Инк. filed Critical Астросайт Фармасьютикалс, Инк.
Publication of EA202190576A1 publication Critical patent/EA202190576A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

В настоящем изобретении предложены соединения и способы их применения для лечения некоторых расстройств и состояний, например, повреждений головного мозга, таких как инсульт или черепно-мозговые травмы.
EA202190576A 2018-09-26 2019-09-26 Полиморфные соединения и их применение EA202190576A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862736979P 2018-09-26 2018-09-26
PCT/US2019/053076 WO2020069068A1 (en) 2018-09-26 2019-09-26 Polymorphic compounds and uses thereof

Publications (1)

Publication Number Publication Date
EA202190576A1 true EA202190576A1 (ru) 2021-09-03

Family

ID=69885558

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190576A EA202190576A1 (ru) 2018-09-26 2019-09-26 Полиморфные соединения и их применение

Country Status (12)

Country Link
US (2) US10765693B2 (ru)
EP (1) EP3856741A4 (ru)
JP (2) JP2022502405A (ru)
KR (1) KR20210093864A (ru)
CN (1) CN112930349A (ru)
AU (1) AU2019346585A1 (ru)
BR (1) BR112021005290A2 (ru)
CA (1) CA3113250A1 (ru)
EA (1) EA202190576A1 (ru)
IL (1) IL281718A (ru)
MX (1) MX2021003515A (ru)
WO (1) WO2020069068A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018071560A2 (pt) 2016-04-21 2019-02-12 Astrocyte Pharmaceuticals, Inc. compostos e métodos para tratar condições neurológicas e cardiovasculares
EP3749322A4 (en) 2018-02-09 2021-11-17 Astrocyte Pharmaceuticals, Inc. COMPOUNDS AND METHODS FOR THE TREATMENT OF ADDICTION AND RELATED DISORDERS
IL310045A (en) 2021-07-12 2024-03-01 Acadia Pharm Inc Crystalline forms of tropintide
KR20240122782A (ko) * 2021-11-22 2024-08-13 아스트로사이트 파마슈티컬스, 인코포레이티드 신경학적 및 심혈관 상태를 치료하는 방법
WO2024097387A1 (en) * 2022-11-03 2024-05-10 Astrocyte Pharmaceuticals, Inc. Compositions for intravenous administration

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7331094A (en) 1993-07-13 1995-02-13 United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The A3 adenosine receptor agonists
US7348315B2 (en) 1995-03-23 2008-03-25 The University Of Connecticut Methods of treating heart failure with modified ATP, ADP and AMP compounds
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US6586413B2 (en) 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
KR20020071931A (ko) * 2000-01-07 2002-09-13 트렌스폼 파마수티컬스 인코퍼레이티드 다양한 고체-형태들의 고도의 자료 처리 편성, 확인 및분석
AU2001230913B2 (en) * 2000-01-14 2005-06-30 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methanocarba cycloalkyl nucleoside analogues
US7589075B2 (en) 2001-01-16 2009-09-15 Can-Fite Biopharma Ltd. Use of an adenosine A3 receptor agonist for inhibition of viral replication
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
AU2003294462C1 (en) 2002-11-21 2011-06-30 University Of Utah Research Foundation Purinergic modulation of smell
GB0405009D0 (en) * 2004-03-05 2004-04-07 Cambridge Biotechnology Ltd Analgesics
US7825126B2 (en) 2004-09-09 2010-11-02 The United States Of America As Represented By The Department Of Health And Human Services Purine derivatives as A3 and A1 adenosine receptor agonists
WO2006091905A1 (en) * 2005-02-25 2006-08-31 Gilead Sciences, Inc. Bicyclo (3.1.0) hexane derivatives as antiviral compounds
WO2007020018A1 (en) 2005-08-12 2007-02-22 Universite Libre De Bruxelles Use of purinergic and pyrimidinergic receptor agonists for dendritic cells based immunotherapies
WO2007139775A2 (en) 2006-05-23 2007-12-06 University Of Connecticut N-methanocarba derivatives to treat cardiac diseases
WO2008021552A2 (en) 2006-08-18 2008-02-21 Duke University Biased ligands and methods of identifying same
WO2008156513A2 (en) 2007-03-29 2008-12-24 University Of Connecticut Methods to protect skeletal muscle against injury
EP2227234B1 (en) 2007-10-15 2014-05-07 Can-Fite Biopharma Ltd. Method for inducing hepatocyte proliferation and uses thereof
CN101925610A (zh) 2007-11-23 2010-12-22 巴尔-伊兰大学 不可水解的二磷酸核苷或三磷酸核苷衍生物及其用途
ES2531828T3 (es) 2008-03-31 2015-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Derivados de purina como agonistas selectivos de los receptores A3 de adenosina
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
CA2721927C (en) 2008-04-21 2014-01-28 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US8399018B2 (en) 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
EP2331542B1 (en) 2008-08-01 2016-07-27 The United States of America, as Represented by The Secretary, Department of Health and Human Services A3 adenosine receptor antagonists and partial agonists
US8685372B2 (en) 2009-04-15 2014-04-01 The Regents Of The University Of California Peptides and aptamers for targeting of neuron or nerves
EP2507241A1 (en) 2009-12-02 2012-10-10 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Methanocarba adenosine derivatives and dendrimer conjugates thereof
WO2011077435A1 (en) 2009-12-22 2011-06-30 Bar-Ilan University Compositions and methods for reducing intraocular pressure
AU2011217815B2 (en) 2010-02-22 2015-03-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services AMP derivatives for treating cardiac diseases
US8691775B2 (en) 2010-04-19 2014-04-08 Back Bay Scientific, Llc Use of drugs that activate P2Y receptors to enhance synaptogenesis
US9132131B2 (en) 2011-04-21 2015-09-15 Saint Louis University Use of adenosine A3 receptor agonists for treatment of neuropathic pain
WO2013049725A2 (en) 2011-09-30 2013-04-04 Tufts University Methods of using adenosine a1 receptor activation for treating depression
CA2904180C (en) 2013-03-13 2022-05-10 Tufts University Uridine nucleoside derivatives, compositions and methods of use
CN110003212B (zh) 2013-11-27 2022-12-06 美国卫生和人力服务部 A3腺苷受体激动剂
AU2016214975A1 (en) 2015-02-04 2017-08-10 Baker Heart and Diabetes Institute A method of treatment and compounds for use therein
BR112018071560A2 (pt) 2016-04-21 2019-02-12 Astrocyte Pharmaceuticals, Inc. compostos e métodos para tratar condições neurológicas e cardiovasculares
EP3749322A4 (en) 2018-02-09 2021-11-17 Astrocyte Pharmaceuticals, Inc. COMPOUNDS AND METHODS FOR THE TREATMENT OF ADDICTION AND RELATED DISORDERS

Also Published As

Publication number Publication date
IL281718A (en) 2021-05-31
JP2022502405A (ja) 2022-01-11
CA3113250A1 (en) 2020-04-02
EP3856741A1 (en) 2021-08-04
MX2021003515A (es) 2021-05-27
KR20210093864A (ko) 2021-07-28
EP3856741A4 (en) 2022-06-22
AU2019346585A1 (en) 2021-04-29
WO2020069068A1 (en) 2020-04-02
WO2020069068A9 (en) 2020-05-14
JP2024114885A (ja) 2024-08-23
US20200093848A1 (en) 2020-03-26
CN112930349A (zh) 2021-06-08
US10765693B2 (en) 2020-09-08
US11324769B2 (en) 2022-05-10
BR112021005290A2 (pt) 2021-06-22
US20210077518A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
EA201892008A1 (ru) Соединения и способы лечения неврологических и сердечно-сосудистых состояний
EA202190576A1 (ru) Полиморфные соединения и их применение
MX2022013526A (es) Degradadores de proteinas y usos de los mismos.
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
MD3436461T2 (ro) Compuși pirolotriazină ca inhibitori TAM
CY1121938T1 (el) Αγωνιστες apj 4-υδροξυ-3-(ετερο¶ρυλ)πυριδινο-2-ονης για χρηση στη θεραπεια καρδιαγγειακων διαταραχων
EA201990912A1 (ru) Анти-lag-3 антитела и их композиции
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EA201991553A1 (ru) (аза)индол-, бензотиофен- и бензофуран-3-сульфонамиды
EA201990187A1 (ru) Антипролиферационные средства на основе пиримидина
CL2018000375A1 (es) 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1.
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
EA201790992A1 (ru) Иммунорегуляторные агенты
EA201691134A1 (ru) Новые ингибиторы глутаминазы
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201790998A1 (ru) Иммуннорегуляторные агенты
EA201792604A1 (ru) Ингибиторы аутотаксина и их применения
EA201990400A1 (ru) Соединения и композиции и их применение
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
EA201990257A1 (ru) Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
MA53664A (fr) Composés destinés au traitement de certaines leucémies
EA202091655A1 (ru) Композиции и способы лечения нарушений сетчатки
EA201992302A1 (ru) Соединения, используемые в качестве ингибиторов alcat1
EA201991898A1 (ru) Двойные ингибиторы magl и faah